Medtronic Q2 Earnings: Diabetes And Neuroscience Revenue Boost Growth, Raises Annual Outlook

Tuesday, Medtronic Plc MDT reported second-quarter 2025 sales of $8.40 billion, beating the consensus of $8.27 billion. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.

Revenue increased 5.3% year over year, as reported, and 5% on an organic basis.

Also Read: Medtronic Recalls MiniMed Pump Due To Battery Life Concerns

Cardiovascular segment revenue reached $3.102 billion, up 6.1% year over year as reported, and increased 5.6% organically,  with a high-single-digit increase in Structural Heart & Aortic and mid-single-digit increases in  Cardiac Rhythm & Heart Failure and Coronary & Peripheral Vascular, all on an organic basis.

Neuroscience revenues of $2.45 billion increased 7.1% as reported and 6.7% organically, with a low-double-digit increase in Neuromodulation and mid-single-digit increases in Cranial & Spinal Technologies and Specialty Therapies, all on an organic basis.

Medical Surgical revenue of $2.13 billion increased by 1.2% as reported and increased by 0.7% organically, with a low-single-digit organic increase in Acute Care & Monitoring and flat organic result in Surgical & Endoscopy.

Surgical & Endoscopy year-over-year results were affected by a difficult comparison from the prior year supply recovery in Surgical and increased high-single digits sequentially.

Diabetes revenue of $686 million increased by 12.4%, as reported, and by 11% organic.

“Our momentum is building as we keep executing on our commitments, delivering yet another consecutive quarter of strong results that came in ahead of expectations,” said Geoff Martha, Medtronic chairman and chief executive officer.

Guidance: Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up from the prior 4.5%-5%.

If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%.

Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.

Price Action: MDT stock is down 3.52% at $84.53 at the last check on Tuesday.

Read Next:

• Moderna Remains Confident Despite Political Concerns Over Vaccine Safety and HHS Nomination

Photo by Tony Webster via Wikimedia Commons